Efficacy of rituximab in refractory neuromyelitis optica - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Multiple Sclerosis Journal Année : 2016

Efficacy of rituximab in refractory neuromyelitis optica


BACKGROUND: Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy. OBJECTIVE: The purpose of this study was to assess RTX as a maintenance therapy in RNMO. METHODS: Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months. RESULTS: After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 (p<0.001) and median EDSS from 5 to 3 (p=0.02). Body mass index (BMI) was predictive of EDSS worsening. CONCLUSIONS: RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.
Fichier non déposé

Dates et versions

hal-01889926 , version 1 (08-10-2018)



N. Collongues, D. Brassat, E. Maillart, Pierre Labauge, J Ouallet, et al.. Efficacy of rituximab in refractory neuromyelitis optica. Multiple Sclerosis Journal, 2016, 22 (7), pp.955 - 959. ⟨10.1177/1352458515602337⟩. ⟨hal-01889926⟩
23 Consultations
0 Téléchargements



Gmail Facebook X LinkedIn More